Ocumetics Strengthens Balance Sheet with $1.4 Million Debt Conversion Ahead of Key Clinical Milestones
Ocumetics Technology Corp. converts $1.4 million of debenture principal into equity, reducing debt by 35% and improving financial flexibility as it prepares for FDA submission.
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced that debentureholders have converted $1.4 million of their principal into common shares at $0.32 per share, resulting in the issuance of 4,375,000 common shares. This conversion represents a 35% reduction in the company's previously outstanding debenture principal of $4 million, significantly strengthening its balance sheet.
The debt-to-equity conversion is expected to improve Ocumetics' financial flexibility and reduce ongoing interest costs while aligning investor interests with the continued advancement of its technology platform and clinical development objectives. The company is actively progressing toward key milestones in its ongoing patient study program, including preparation for an Investigational Device Exemption (IDE) submission to the U.S. Food and Drug Administration.
"These debenture conversions reflect the confidence our investors and debenture holders continue to show in Ocumetics and our long-term vision," said Dean Burns, President and CEO. "We are actively managing our investments and stakeholder relationships as we continue to advance our patient study and focus on achieving the next major milestones for the Company."
Ocumetics is developing a dynamic intraocular lens designed to fit within the eye's natural lens compartment, potentially eliminating the need for corrective lenses. The lens aims to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses and without perceptible time lag. The company is currently in the first-in-human early feasibility study phase.
The debt conversion marks a strategic move to strengthen Ocumetics' financial position as it approaches critical regulatory and clinical milestones. By reducing debt and interest obligations, the company can allocate more resources toward its research and development efforts and the planned IDE submission. The transaction also signals strong support from debentureholders, who have elected to convert their debt into equity, betting on the company's long-term success.
For further information, please visit the company's official website or contact Investor Relations. This news release includes forward-looking statements subject to risks and uncertainties, and actual results may differ materially from those anticipated.